Mustang Bio (MBIO) Share-based Compensation (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Share-based Compensation of $22000.0 for Q1 2026, down 42.11% year-over-year from $38000.0 in Q1 2025, and down 4.35% quarter-over-quarter from $23000.0 in Q4 2025.
Mustang Bio (MBIO) Share-based Compensation (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Share-based Compensation for 11 consecutive years, with $22000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 42.11% year-over-year to $22000.0; the TTM figure through Mar 2026 stood at $113000.0 (down 79.53% YoY), while the FY2025 annual figure was $129000.0, down 78.17% from the prior year.
- Share-based Compensation declined to $22000.0 in Q1 2026 per MBIO's latest filing, from $23000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.2 million in Q1 2022 and bottomed at -$1.9 million in Q4 2022.
- Historically, Share-based Compensation has averaged $361941.2 across 5 years, with a median of $45000.0 in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation surged 137.79% — and 2024, when it plunged 1475.56%.
- Mustang Bio's Share-based Compensation stood at -$1.9 million in 2022, then soared by 137.79% to $729000.0 in 2023, then jumped by 49.66% to $1.1 million in 2024, then slumped by 97.89% to $23000.0 in 2025, then fell by 4.35% to $22000.0 in 2026.
- Business Quant data shows MBIO's Share-based Compensation at $22000.0 in Q1 2026, $23000.0 in Q4 2025, and $23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21,000.00 |
| Jun 30, 2026 | 21,000.00 |
| Mar 31, 2026 | 22,000.00 |
| Mar 31, 2026 | 22,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Mar 31, 2025 | 38,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 42,000.00 |
| Sep 30, 2024 | 42,000.00 |
| Jun 30, 2024 | -619,000.00 |
| Jun 30, 2024 | -619,000.00 |
| Mar 31, 2024 | 76,000.00 |
| Mar 31, 2024 | 76,000.00 |